---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-118699"
form_type: "8-K"
ticker: "DMRA"
cik: "0001800315"
company_name: "Damora Therapeutics, Inc."
filed_at: "2026-03-23T23:59:59+00:00"
generated_at: "2026-05-15T09:23:15.775847+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Damora Therapeutics appoints Jennifer Jarrett as CEO, adds two directors, names chairman

## Summary
- Jennifer Jarrett appointed President and CEO, effective March 30, 2026; also joins board.
- Three directors (Munshi, Goldfischer, Dallas) resigned March 23; not due to disagreements.
- New directors: Cameron Turtle (CEO, Spyre Therapeutics) and Mike Landsittel (ex-CFO, Blueprint Medicines).
- Peter Harwin named Chairman of the Board.
- Jarrett receives $695k base salary, 55% target bonus, 500k RSUs and 1.5M stock options.

## SEC filing metadata
- accession: 0001193125-26-118699
- form_type: 8-K
- ticker: DMRA
- cik: 0001800315
- company_name: Damora Therapeutics, Inc.
- filed_at: 2026-03-23T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800315/000119312526118699/0001193125-26-118699-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800315/000119312526118699/dmra-20260320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-118699
- JSON: https://secwatch.observer/filing/0001193125-26-118699.json
- Plain text: https://secwatch.observer/filing/0001193125-26-118699.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.